



PRIOR AUTHORIZATION REQUEST

Rukobia

Patient Information:

| | |
|-------------------|--|
| Name: | |
| Member ID: | |
| Address: | |
| City, State, Zip: | |
| Date of Birth: | |

Prescriber Information:

| | |
|-------------------|--|
| Name: | |
| NPI: | |
| Phone Number: | |
| Fax Number: | |
| Address: | |
| City, State, Zip: | |

Requested Medication

| | |
|-----------------------------|--|
| Rx Name: | |
| Rx Strength: | |
| Rx Quantity: | |
| Rx Frequency: | |
| Rx Route of Administration: | |
| Diagnosis and ICD Code: | |

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for ALL PA requests.

| | | | |
|---|--|-----|----|
| 1 | Is the patient 18 years of age or older? [If no, no further questions.] | Yes | No |
| 2 | Is the requested medication prescribed by or in consultation with a physician who specializes in the treatment of HIV infection? [If no, no further questions.] | Yes | No |
| 3 | What is the diagnosis or indication? <input type="checkbox"/> HIV type 1 (HIV-1) infection (If checked, go to 4) <input type="checkbox"/> Other (If checked, no further questions) | | |
| 4 | Is this request for initial therapy or for a continuation of therapy? | | |

If you have any
questions, call:
1-888-258-8250

PRIOR AUTHORIZATION REQUEST

☐ Initial (If checked, go to 5)

☐ Continuation (If checked, go to 9)

| | | | |
|----|--|-----|----|
| 5 | Is the patient failing a current antiretroviral regimen for HIV? [If no, no further questions.] | Yes | No |
| 6 | Has the patient exhausted at least FOUR of the following antiretroviral classes defined as elimination of all antiretrovirals within a given class due to demonstrated or projected resistance to the agent(s) in that class: (a) Nucleoside reverse transcriptase inhibitor (Examples include abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, tenofovir alafenamide, zidovudine); (b) Non-nucleoside reverse transcriptase inhibitor (Examples include delaviridine, efavirenz, etravirine, nevirapine, nevirapine XR, rilpivirine); (c) Protease inhibitor (Examples include atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir); (d) Fusion inhibitor (Examples include Fuzeon [enfuvirtide for injection]); (e) Integrase strand transfer inhibitor (Examples of integrase strand transfer inhibitors include raltegravir, dolutegravir, elvitegravir); (f) CCR5 antagonist (Examples include Selzentry [maraviroc tablets])? [If yes, skip to question 8.] | Yes | No |
| 7 | Has the patient exhausted at least FOUR of the following antiretroviral classes defined as elimination of all antiretrovirals within a given class due to significant intolerance: (a) Nucleoside reverse transcriptase inhibitor (Examples include abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil fumarate, tenofovir alafenamide, zidovudine); (b) Non-nucleoside reverse transcriptase inhibitor (Examples include delaviridine, efavirenz, etravirine, nevirapine, nevirapine XR, rilpivirine); (c) Protease inhibitor (Examples include atazanavir, darunavir, fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, tipranavir); (d) Fusion inhibitor (Examples include Fuzeon [enfuvirtide for injection]); (e) Integrase strand transfer inhibitor (Examples of integrase strand transfer inhibitors include raltegravir, dolutegravir, elvitegravir); (f) CCR5 antagonist (Examples include Selzentry [maraviroc tablets])? [If no, no further questions.] | Yes | No |
| 8 | Will the requested medication be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents? [No further questions.] | Yes | No |
| 9 | Will the requested medication continue to be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents? [If no, no further questions.] | Yes | No |
| 10 | Has the patient responded to a Rukobia-containing regimen, as determined by the prescriber? [Note: Examples of a response are HIV RNA less than 40 cells/mm3, HIV-1 RNA greater than or equal to 0.5 log10 reduction from baseline in viral load.] | Yes | No |

**If you have any
questions, call:
1-888-258-8250**



PRIOR AUTHORIZATION REQUEST

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any
questions, call:
1-888-258-8250